Distinct karyotypic and mutational landscape in trisomy AML.

Area of Science:

• Hematology
• Genetics
• Oncology

Background:

• Trisomy karyotype is observed in 5%-10% of acute myeloid leukemia (AML) cases.
• The specific mutational landscape and prognostic implications of trisomy AML remain incompletely understood.

Purpose of the Study:

• To define the distinct mutational landscape of trisomy AML.
• To investigate the prognostic significance of various mutations within trisomy AML.
• To compare trisomy AML with cytogenetically normal (CN) AML.

Main Methods:

• Analysis of a cohort of 156 trisomy AML patients.
• Comparison with a cohort of 615 cytogenetically normal (CN) AML patients.
• Evaluation of mutational profiles and correlation with clinical outcomes.

Main Results:

• Trisomy AML exhibits a unique mutational landscape, with increased prevalence of SMC1A, N/KRAS, ASXL1, and BCOR mutations.
• Fewer CEBPA^bZIP and NPM1 mutations were observed in younger trisomy AML patients (≤60), and fewer NPM1 mutations in older patients (>60).
• NRAS mutations were linked to poor outcomes, while DNMT3A and FLT3-ITD mutations had a neutral prognostic effect in trisomy AML.

Conclusions:

• Trisomy AML is biologically distinct from CN-AML.
• Specific mutations like NRAS have prognostic relevance in trisomy AML.
• Understanding these differences is crucial for refining AML classification and treatment strategies.